Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BionimeTPE:4737 -2.20%64 Buyback Yield % is -0.12 as of Jul. 15, 2026. GuruFocus rates TPE:4737 with a GF Score™ of 64/100 and a GF Value™ of NT$58.78 (Fairly Valued). The stock has 7 warning signs investors should review. Among 347 Medical Devices & Instruments companies, Bionime ranks better than 54.18% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Bionime's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4737 vs ISRG, BDX, MDLN: Buyback Yield % Comparison
For the Medical Instruments & Supplies subindustry, Bionime's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionime Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bionime's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Bionime's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionime (TPE:4737) has a Buyback Yield % of -0.12 as of Jul. 15, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Bionime and its competitors. According to the industry distribution chart, Bionime ranks #159 out of 347 companies in the Medical Devices & Instruments industry, placing it in the top 45.8%.
Is Bionime's Buyback Yield % too high?
Bionime's current Buyback Yield % is -0.12. Based on the distribution chart, Bionime ranks #159 out of 347 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bionime has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bionime's Buyback Yield % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bionime ranks #159 out of 347 companies for Buyback Yield %. This puts Bionime in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Bionime and its competitors. Bionime's current Buyback Yield % is -0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionime stock overvalued right now?
Based on GuruFocus' analysis, Bionime (TPE:4737) is currently considered Fairly Valued. The stock's GF Value™ is NT$58.78, compared to a current price of NT$62.20 — trading 5.8% above its estimated fair value. The current Buyback Yield % is -0.12. Bionime's overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Bionime (TPE:4737), the current Buyback Yield % is -0.12 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bionime (TPE:4737) Overvalued in 2026?
Based on GuruFocus' analysis, Bionime stock appears to be overvalued.
The current stock price of NT$62.20 is trading 5.8% above its estimated GF Value™ of NT$58.78.
GuruFocus considers Bionime to be Fairly Valued.
Key valuation signals for TPE:4737:
Buyback Yield %: -0.12
GF Value™: NT$58.78 vs. price of NT$62.20 (5.8% above fair value)
No single metric tells the full story. See the TPE:4737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bionime Corp is engaged in the manufacturing and selling of medical instruments, providing biotechnology services, examining pharmaceuticals, and selling precision instruments. The company's revenue is derived from the sale of blood glucose meters and test strips to domestic and foreign clients. Geographically, it operates in Algeria, China, Switzerland, the United States, Belarus, Egypt, the United Arab Emirates, and other countries, of which it derives the maximum revenue from Algeria.
64GF Score
Get the complete analysis for TPE:4737
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4737 has been successfully added to your 
